Profile data is unavailable for this security.
About the company
Mankind Pharma Limited is an India-based pharmaceutical company. It is engaged in developing, manufacturing, and marketing a range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It offers healthcare solutions for a range of healthcare needs with a portfolio that includes anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/ central nervous system, vitamins, minerals and nutrients and respiratory therapies. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others. Its branded product portfolio spans women’s health, fertility and critical care, with several brands in their respective therapy areas. Its subsidiaries include Lifestar Pharma Private Limited, Magnet Labs Private Limited, Jaspack Industries Private Limited, and others.
- Revenue in INR (TTM)110.18bn
- Net income in INR21.15bn
- Incorporated1991
- Employees19.54k
- LocationMankind Pharma Ltd262, Okhla Industrial Estate, Phase-IIINEW DELHI 110020IndiaIND
- Phone+91 1 147476600
- Fax+91 1 146541382
- Websitehttps://www.mankindpharma.com/
Mergers & acquisitions
| Acquired company | MANKIND:NSI since announced | Transaction value |
|---|---|---|
| Bharat Serums & Vaccines Ltd | 21.08% | 1.64bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbott India Ltd | 60.66bn | 12.85bn | 576.17bn | 3.81k | 44.85 | 16.36 | 42.47 | 9.50 | 604.57 | 604.57 | 2,854.72 | 1,657.05 | 1.27 | 5.32 | 15.71 | 15,904,690.00 | 26.82 | 20.92 | 36.97 | 28.59 | 45.09 | 44.20 | 21.18 | 17.26 | 1.71 | 131.36 | 0.0169 | 77.06 | 9.35 | 9.72 | 26.52 | 21.68 | 31.08 | 52.32 |
| Alkem Laboratories Ltd | 127.06bn | 21.22bn | 670.13bn | 17.28k | 31.57 | 5.83 | 27.09 | 5.27 | 177.51 | 177.51 | 1,062.75 | 961.22 | 0.7931 | 1.72 | 5.14 | 7,354,390.00 | 13.49 | 11.88 | 18.66 | 17.50 | 63.10 | 59.26 | 17.01 | 13.94 | 1.97 | 12.21 | 0.1104 | 29.82 | 9.21 | 11.48 | 82.47 | 18.75 | -13.30 | 20.11 |
| Aurobindo Pharma Ltd | 302.95bn | 35.82bn | 708.58bn | 8.80k | 19.91 | 2.29 | 13.85 | 2.34 | 61.29 | 61.29 | 518.43 | 531.65 | 0.6585 | 1.27 | 6.04 | 34,437,900.00 | 7.79 | 9.24 | 11.08 | 13.43 | 58.76 | 53.30 | 11.83 | 12.72 | 1.10 | 13.69 | 0.2144 | 8.64 | 16.68 | 8.19 | 64.62 | 6.06 | 17.96 | 12.47 |
| Lupin Ltd | 214.31bn | 26.26bn | 932.01bn | 21.87k | 35.58 | 5.96 | 25.40 | 4.35 | 57.42 | 57.42 | 468.54 | 342.91 | 0.8761 | 1.35 | 4.48 | 9,800,284.00 | 10.84 | 1.43 | 16.64 | 2.22 | 68.60 | 58.52 | 12.37 | 2.04 | 1.22 | 11.88 | 0.1797 | 75.03 | 20.25 | 6.41 | 345.15 | 30.18 | -1.17 | 9.86 |
| Zydus Lifesciences Ltd | 214.84bn | 42.78bn | 949.94bn | 26.24k | 22.26 | 4.35 | 18.45 | 4.42 | 42.41 | 42.66 | 212.94 | 216.89 | 0.7495 | 1.75 | 5.01 | 8,187,310.00 | 15.00 | 9.05 | 19.96 | 14.01 | 71.43 | 61.15 | 20.01 | 14.33 | 1.58 | 217.94 | 0.0078 | 16.48 | 13.40 | 8.23 | 95.25 | 15.72 | -3.03 | -3.04 |
| Dr Reddy's Laboratories Ltd | 300.85bn | 53.39bn | 995.78bn | 26.34k | 18.67 | 3.24 | 14.34 | 3.31 | 64.03 | 64.03 | 360.85 | 369.12 | 0.7379 | 1.37 | 3.90 | 11,420,450.00 | 13.31 | 11.37 | 18.14 | 16.02 | 70.69 | 65.86 | 18.03 | 14.63 | 1.36 | 30.69 | 0.1349 | 15.91 | 13.54 | 12.64 | 23.75 | 23.39 | 26.78 | 14.87 |
| Mankind Pharma Ltd | 110.18bn | 21.15bn | 1.03tn | 19.54k | 48.55 | 9.70 | 39.95 | 9.30 | 52.70 | 52.70 | 274.57 | 263.69 | 0.8786 | 2.02 | 9.46 | 5,638,684.00 | 17.05 | -- | 21.79 | -- | 70.48 | -- | 19.41 | -- | 2.37 | 99.72 | 0.0428 | -- | 18.12 | -- | 49.23 | -- | -- | -- |
| Torrent Pharmaceuticals Ltd | 112.25bn | 18.02bn | 1.05tn | 14.92k | 58.25 | 13.99 | 40.37 | 9.35 | 53.25 | 53.25 | 331.63 | 221.72 | 0.7525 | 1.22 | 6.35 | 7,525,369.00 | 12.08 | 8.34 | 17.95 | 13.03 | 75.52 | 71.78 | 16.06 | 13.18 | 0.7444 | 9.32 | 0.2941 | 61.65 | 11.51 | 6.93 | 33.02 | 30.58 | -8.17 | 26.93 |
| Cipla Ltd | 265.12bn | 44.75bn | 1.18tn | 27.76k | 26.46 | 4.17 | 21.42 | 4.46 | 55.39 | 55.39 | 328.19 | 351.20 | 0.803 | 1.58 | 5.08 | 9,549,060.00 | 13.58 | 10.09 | 16.44 | 12.40 | 67.01 | 58.63 | 16.92 | 12.66 | 2.82 | 69.41 | 0.016 | 21.39 | 13.28 | 9.51 | 47.10 | 21.96 | 20.68 | 34.08 |
| Holder | Shares | % Held |
|---|---|---|
| SBI Funds Management Ltd.as of 31 Oct 2024 | 5.96m | 1.49% |
| Axis Asset Management Co. Ltd.as of 31 Oct 2024 | 3.97m | 0.99% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 3.43m | 0.86% |
| SBI Life Insurance Co. Ltd. (Investment Portfolio)as of 31 Aug 2024 | 3.36m | 0.84% |
| Invesco Asset Management (India) Pvt Ltd.as of 31 Oct 2024 | 3.03m | 0.76% |
| Capital Research & Management Co. (World Investors)as of 07 Nov 2024 | 2.97m | 0.74% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 2.31m | 0.58% |
| Canada Pension Plan Investment Boardas of 31 Mar 2024 | 2.29m | 0.57% |
| ICICI Prudential Asset Management Co. Ltd.as of 31 Oct 2024 | 2.13m | 0.53% |
| Tata AIA Life Insurance Co. Ltd.as of 31 Oct 2024 | 2.02m | 0.51% |
